Clinical evidence shows that AposHealth (an FDA-cleared medical device) improves pain, stiffness, and function in people with knee osteoarthritis.
However, it’s uncertain if these improvements are clinically meaningful. The analyses suggest that AposHealth is cost saving by £1,958 per person when compared with standard care if knee surgery is delayed for 5 years. Because the evidence for the potential cost savings is limited, further data collection is recommended to understand if cost savings are made once AposHealth is used in the NHS.
Recent Posts
Real-World Evidence Integration into Cancer HTA: Scotland’s Success Story
How is real-world evidence integration a routine part of Health Technology Assessment (HTA) for cancer medicines in Scotland? Through a successful collaboration between the Cancer Medicines Outcomes Programme–Public Health Scotland (CMOP-PHS) and the Scottish Medicines Consortium (SMC), structure...
Personalised Fertility Endometriosis Care in the UK
The updated NICE fertility guideline introduces a dedicated section for individuals with endometriosis who are struggling to conceive. This change formally recognises personalised fertility endometriosis as a distinct cause of infertility rather than grouping it under unexplained infertility.
EU-India Pharmaceutical Trade: Opportunities and Challenges in Biopharmaceutical Innovation
A European Federation of Pharmaceutical Industries and Associations (EFPIA) statement has welcomed the European Union’s progress in concluding negotiations for a Free Trade Agreement with India. EU-India Pharmaceutical Trade relations have gained strategic importance amid geopolitical uncertainty...